Multiplex in situ immunohistochemical analysis
View Patent ↗A method of in situ immunohistochemical analysis of a biological sample is provided. The method allows for the multiplex and simultaneous detection of multiple antigens, including multiple nuclear antigens, in a tissue sample.
1. A method of detecting whether each of at least three targets are present or absent in a biological sample comprising the steps of:
(a) performing antigen retrieval on the biological sample, wherein said antigen retrieval comprises the steps:
i. de-paraffinize and re-hydrate biological sample and
ii. boil in antigen retrieval buffer;
(b) performing autofluorescence reduction on the biological sample prior to step (a), or step (c), wherein said autofluorescence reduction comprises incubating said biological sample in a solution comprising 1% hydrochloric acid and 70% ethanol;
(c) contacting the biological sample with (1) a first antibody specific for a first target, (2) a first labeling reagent wherein said first labeling reagent comprises an antibody binding moiety for said first antibody and a first fluorescent detection moiety, (3) a second antibody specific for a second target, (4) a second labeling reagent comprising an antibody binding moiety for said second antibody and a second fluorescent detection moiety, (5) a third antibody specific for a third target, and (6) a third labeling reagent comprising an antibody binding moiety for said third antibody and a third fluorescent detection moiety; and
(d) detecting a presence or an absence of each of said first, second and third labeling reagents, respectively, in said biological sample whereby the presence of said first, second or third labeling reagents indicates the presence of said first, second or third targets, respectively, in said biological sample and the absence of said first, second or third labeling reagents indicates the absence of said first, second or third targets, respectively, in said biological sample,
wherein said biological sample is paraffin-embedded human tissue, and wherein prior to step (d) said sample is washed one or more times to remove unbound labeling reagent.
2. The method of claim 1 , further comprising the step of washing said biological sample prior to step (c).
3. The method of claim 1 , wherein the antibody binding moiety for at least one of said first, second or third labeling reagents is a monovalent antibody fragment or a non-antibody protein.
4. The method of claim 3 , wherein said monovalent antibody fragment is a Fab or Fab′ fragment.
5. The method of claim 4 , wherein said Fab or Fab′ fragment is selected from the group consisting of an anti-Fc antibody fragment, an anti-kappa light chain antibody fragment, an anti-lambda light chain antibody fragment, and a single chain antibody fragment.
6. The method of claim 3 , wherein said monovalent antibody fragment is derived from a monoclonal antibody or a polyclonal antibody.
7. The method of claim 3 , wherein said nonantibody protein is selected from the group consisting of a protein G, a protein A, a protein L, and a lectin.
8. The method of claim 1 , wherein at least one of said targets is a nuclear protein or an oncoprotein.
9. The method of claim 1 , wherein the presence of at least one of said targets is indicative of tumor cell heterogeneity.
10. The method of claim 1 wherein at least one of said targets is an androgen receptor, a cytokeratin 18, or a PTEN protein.
11. The method of claim 1 , wherein at least one of said antibodies is a monoclonal antibody.
12. The method of claim 1 , wherein step (c) comprises forming a complex between at least one of said labeling reagents and said antibodies within a tissue section.
13. The method of claim 1 , wherein said biological sample is substantially free of nucleic acids before said detecting step.
14. The method of claim 1 , further comprising the step of tissue permeabilization prior to step (c).
15. The method of claim 1 , further comprising contacting said biological sample with an antibody specific for a fourth target and a fourth fluorescent labeling reagent.
16. The method of claim 15 , further comprising contacting said biological sample with an antibody specific for a fifth target and a fifth fluorescent labeling reagent.
17. The method of claim 16 , further comprising contacting said biological sample with an antibody specific for a sixth target and a sixth fluorescent labeling reagent.
18. The method of claim 17 , further comprising contacting said biological sample with an antibody specific for a seventh target and a seventh fluorescent labeling reagent.
19. The method of claim 1 , wherein at least one of said targets is selected from the group consisting of Androgen Receptor, Ki67, Cyclin D1, P-PKC zeta, Alpha-methylacyl-CoA racemase (AMACR), Epidermal Growth Factor Receptor (EGFR), PI3K, NFkB, P-KDR, vascular endothelial growth factor (VEGF), CD34, pAKT and Caspase 3a.
20. The method of claim 1 , wherein said biological sample is at least 10 years old.
21. A method of detecting whether each of at least three targets are present or absent in a biological sample comprising the steps of:
(a) performing antigen retrieval on the biological sample, wherein said antigen retrieval comprises the steps:
i. de-paraffinize and re-hydrate biological sample and
ii. boil in antigen retrieval buffer;
(b) performing autofluorescence reduction on the biological sample prior to step (a), or step (c), wherein said autofluorescence reduction comprises incubating said biological sample in a solution comprising 1% hydrochloric acid and 70% ethanol;
(c) contacting said biological sample with
i. a first complex, comprising an first antibody specific for a first target and a first labeling reagent wherein said labeling reagent comprises an antibody binding moiety specific for said first antibody and a first fluorescent detection moiety;
ii. a second antibody specific for a second target and a second labeling reagent comprising an antibody binding moiety specific for said second antibody and a second fluorescent detection moiety; and
iii. a third antibody specific for a third target, and a third labeling reagent comprising an antibody binding moiety for said third antibody and a third fluorescent detection moiety;
(d) detecting a presence or an absence of each of said first, second and third labeling reagents, respectively, in said biological sample whereby the presence of said first, second or third labeling reagent indicates the presence of said first, second or third target, respectively in said biological sample and the absence of said first, second or third labeling reagent indicates the absence of said first, second or third target, respectively, in said biological sample,
wherein said biological sample is paraffin-embedded human tissue, and wherein prior to step (d) said sample is washed one or more times to remove unbound labeling reagent.
22. The method of claim 21 , further comprising the step of washing said biological sample prior to step (c).
23. The method of claim 21 , further comprising the step of tissue permeabilization prior to step (c).
24. The method of claim 21 , wherein the antibody binding moiety at least one of said first, second or third labeling reagents is a monovalent antibody fragment or a non-antibody protein.
25. The method of claim 24 , wherein said monovalent antibody fragment is a Fab or Fab′ fragment.
26. The method of claim 24 , wherein said Fab or Fab′ fragment is selected from the group consisting of an anti-Fc antibody fragment, an anti-kappa light chain antibody fragment, an anti-lambda light chain antibody fragment, and a single chain antibody fragment.
27. The method of claim 24 , wherein said monovalent antibody fragment is derived from a monoclonal antibody or a polyclonal antibody.
28. The method of claim 24 , wherein said nonantibody protein is selected from the group consisting of a protein G, a protein A, a protein L, and a lectin.
29. The method of claim 21 , wherein said biological sample is at least 10 years old.
30. The method of claim 21 , wherein at least one of said targets is a nuclear antigen or an oncoprotein.
31. The method of claim 21 , wherein the presence of at least one of said targets is indicative of tumor cell heterogeneity.
32. The method of claim 21 , wherein at least one of said targets is an androgen receptor, a cytokeratin 18, or a PTEN protein.
33. The method of claim 21 , wherein at least one of said targets is selected from the group consisting of Androgen Receptor, Ki67, Cyclin D1, P-PKC zeta, Alpha-methylacyl-CoA racemase (AMACR), Epidermal Growth Factor Receptor EGFR), PI3K, NFkB, P-KDR, vascular endothelial growth factor (VEGF), CD34, pAKT and Caspase 3a.
34. The method of claim 21 , wherein at least one of said first, second and/or third antibodies is a monoclonal antibody.
35. The method of claim 21 , wherein step (c) comprises forming a complex between at least one of said labeling reagents and said antibodies within a tissue section.
36. The method of claim 21 , further comprising contacting said biological sample with an antibody specific for a fourth target and a fourth fluorescent labeling reagent.
37. The method of claim 36 , further comprising contacting said biological sample with an antibody specific for a fifth target and a fifth fluorescent labeling reagent.
38. The method of claim 37 , further comprising contacting said biological sample with an antibody specific for a sixth target and a sixth fluorescent labeling reagent.
39. The method of claim 38 , further comprising contacting said biological sample with an antibody specific for a seventh target and a seventh fluorescent labeling reagent.